DocGo マネジメント
マネジメント 基準チェック /24
DocGoの CEO はLee Bienstockで、 Sep2023年に任命され、 の在任期間は 2.67年です。 の年間総報酬は$ 3.57Mで、 22%給与と78%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.68%を直接所有しており、その価値は$ 411.16K 。経営陣と取締役会の平均在任期間はそれぞれ3.4年と2年です。
主要情報
Lee Bienstock
最高経営責任者
US$3.6m
報酬総額
| CEO給与比率 | 21.98% |
| CEO在任期間 | 2.7yrs |
| CEOの所有権 | 0.7% |
| 経営陣の平均在職期間 | 3.4yrs |
| 取締役会の平均在任期間 | 2yrs |
経営陣の近況
Recent updates
分析記事 • May 14
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
DocGo Inc. ( NASDAQ:DCGO ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to...
ナラティブの更新 • May 14
DCGO: Transport EBITDA And 2026 Guidance Will Support Future Upside Potential
Narrative Update The consensus analyst price target for DocGo has been reduced toward the mid single digit range, with cuts such as the move from $4.00 to $2.50. Analysts are factoring in mixed Q4 results, modestly higher 2026 transport guidance, updated fair value estimates near $1.87, a slightly higher discount rate of about 7.3%, revised revenue growth assumptions around 4.2%, a profit margin assumption near 6.1%, and a lower future P/E closer to 10.8x.
ナラティブの更新 • Apr 23
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.ナラティブの更新 • Apr 07
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.ナラティブの更新 • Mar 24
DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
ナラティブの更新 • Mar 10
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.ナラティブの更新 • Feb 22
DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).ナラティブの更新 • Feb 08
DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.ナラティブの更新 • Jan 24
DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.ナラティブの更新 • Jan 10
DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).ナラティブの更新 • Dec 26
DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.ナラティブの更新 • Dec 12
DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.分析記事 • Sep 26
Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...分析記事 • May 16
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the DocGo Inc. ( NASDAQ:DCGO ) share price has dived 38% in the last thirty days...分析記事 • Apr 16
Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw significant share price movement during recent...分析記事 • Mar 06
We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Despite posting healthy earnings, DocGo Inc.'s ( NASDAQ:DCGO ) stock has been quite weak. We have done some analysis...分析記事 • Mar 01
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Feb 11
Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
DocGo Inc. ( NASDAQ:DCGO ) shareholders have had their patience rewarded with a 33% share price jump in the last month...
新しいナラティブ • Sep 24
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.分析記事 • Aug 05
DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
DocGo Inc.'s ( NASDAQ:DCGO ) price-to-earnings (or "P/E") ratio of 15.3x might make it look like a buy right now...分析記事 • Jul 17
At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw a decent share price growth of 20% on the...分析記事 • Jun 11
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Mar 20
DocGo: Upside Remains Attractive After Share Price Decline
Summary DocGo stock receives a buy rating due to attractive upside potential and commendable execution demonstrated by management. Recent results show strong revenue growth and margin expansion, driven by steady contracts and growth in trip volumes and average price. Management's positive commentary, impressive pipeline, and plans for RFP submissions in FY24 indicate continued momentum and cross-sell success. Read the full article on Seeking Alpha分析記事 • Feb 13
Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 05
DocGo: Good Performance, Trust Issues
Summary DocGo has recently faced a series of negative events, including criticism from the NY Times, Comptroller contract rejection, CEO departure on false CV allegations, and a short report. Despite these challenges, the company presented strong Q3 2023 results, positively revised FY 2023 guidance, addressed the short report, announced new partnerships and a share repurchase program. Investors must decide if they should trust DocGo's performance and financials or let the dust settle first. Read the full article on Seeking Alpha分析記事 • Jan 25
Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$188m |
| Dec 31 2025 | US$4m | US$785k | -US$182m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$18m |
| Mar 31 2025 | n/a | n/a | -US$641k |
| Dec 31 2024 | US$8m | US$785k | US$20m |
| Sep 30 2024 | n/a | n/a | US$31m |
| Jun 30 2024 | n/a | n/a | US$30m |
| Mar 31 2024 | n/a | n/a | US$22m |
| Dec 31 2023 | US$11m | US$582k | US$7m |
| Sep 30 2023 | n/a | n/a | US$7m |
| Jun 30 2023 | n/a | n/a | US$6m |
| Mar 31 2023 | n/a | n/a | US$20m |
| Dec 31 2022 | US$4m | US$415k | US$35m |
報酬と市場: Leeの 総報酬 ($USD 3.57M ) は、 US市場 ($USD 638.05K ) の同規模の企業の平均を上回っています。
報酬と収益: Leeの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Lee Bienstock (40 yo)
2.7yrs
在職期間
US$3,571,951
報酬
Mr. Lee Bienstock served as President at DocGo Inc. since December 31, 2022 until September 15, 2023. He served as Chief Operating Officer at DocGo Inc. since March 2022 until September 15, 2023 and serves...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$3.57m | 0.68% $ 411.2k | |
| Treasurer & CFO | 3.4yrs | US$1.70m | 0.35% $ 210.4k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 56.7k | |
| Chief Information Officer | 1.7yrs | データなし | データなし | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Chief Compliance Officer | 4.2yrs | US$1.84m | 0.15% $ 90.7k | |
| Vice President of Human Resources | no data | データなし | データなし | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | no data | データなし | データなし |
3.4yrs
平均在職期間
53.5yo
平均年齢
経験豊富な経営陣: DCGOの経営陣は 経験豊富 であると考えられます ( 3.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$3.57m | 0.68% $ 411.2k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 56.7k | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | 1.9yrs | データなし | データなし | |
| Independent Director | 4.5yrs | US$225.50k | 0.61% $ 372.3k | |
| Independent Director | 4.5yrs | US$193.00k | 0.45% $ 274.4k | |
| Member of Medical Advisory Board | 1.9yrs | データなし | データなし | |
| Independent Non-Executive Chairman | 1.6yrs | US$400.00k | 0.015% $ 9.2k | |
| Member of Medical Advisory Board | 1.9yrs | データなし | データなし | |
| Independent Director | 3.5yrs | US$208.00k | 0.017% $ 10.1k | |
| Independent Director | 4.5yrs | US$234.25k | 0.057% $ 34.4k | |
| Chairman of Medical Advisory Board | 1.9yrs | データなし | データなし | |
| Member of Medical Advisory Board | 1.9yrs | データなし | データなし |
2.0yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: DCGOの 取締役会 は 経験豊富 ではない ( 2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 06:08 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
DocGo Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |